PACT Pharma to Present New Data Highlighting First-of-its-Kind Personalized Neoantigen TCR T Cell Therapy Platform at SITC 2022

Oral and Poster Presentations Highlight Feasibility of Creating, Manufacturing, and Administering Non-Viral Precision Genome Engineered Tumor Specific T Cell Therapies for Solid Tumors SOUTH SAN FRANCISCO, Calif., Nov. 2, 2022 /PRNewswire/ -- PACT Pharma, Inc., a privately held...

Click to view original post